ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genentech suffered a setback last week when the U.S. Patent & Trademark Office issued a final ruling to reject the company's U.S. patent number 6,331,415. Known as the Cabilly patent, the intellectual property covers antibody production technology that Genentech has licensed to a number of other companies. PTO maintains that the Cabilly patent covers the same ground as an earlier patent issued to the company that expired in March 2005. Genentech plans to appeal the decision, a process that it says could take one to two years.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter